Astellas’ Xospata™ (Gilteritinib) now available in Ireland as monotherapy for the treatment of adult patients who have ...
In the event that patients re-initiate gilteritinib post haematopoietic stem cell transplant (HSCT) as maintenance therapy, gilteritinib treatment should be restricted to patients who are minimal residual disease (MRD)-positive post-transplant1 …